Search research articles
Contact Us
Filters
Showing results (291-300 of 299) with videos related to
Page
of 30
Sort By:
You have reached the last page of results.
This site can display upto 299 results.
Science Translational Medicine
|
April 19, 2019
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V Echeverria, Zhongqi Ge, Sahil Seth, et al.
Nature Metabolism
|
November 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Communications
|
July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Matthew Wong, Yuting Sun, Zhichao Xi, et al.
Nature Metabolism
|
December 19, 2020
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Communications
|
November 7, 2019
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35
Pei Y Liu, Andrew E Tee, Giorgio Milazzo, et al.
Science Translational Medicine
|
November 6, 2015
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Daniel R Carter, Jayne Murray, Belamy B Cheung, et al.
Cell Reports
|
January 10, 2019
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
Yuting Sun, Madhavi Bandi, Timothy Lofton, et al.
Cancer Research
|
September 15, 2020
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
Yuting Sun, Brooke A Meyers, Barbara Czako, et al.
Nature Medicine
|
June 13, 2018
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Jennifer R Molina, Yuting Sun, Marina Protopopova, et al.
Page
of 30
Search research articles
Search
Showing results (291-300 of 299) with videos related to
Sort By:
Page
of 30
You have reached the last page of results.
This site can display upto 299 results.
Science Translational Medicine
|
April 19, 2019
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V Echeverria, Zhongqi Ge, Sahil Seth, et al.
Nature Metabolism
|
November 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Communications
|
July 27, 2019
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma
Matthew Wong, Yuting Sun, Zhichao Xi, et al.
Nature Metabolism
|
December 19, 2020
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
Yu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Communications
|
November 7, 2019
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35
Pei Y Liu, Andrew E Tee, Giorgio Milazzo, et al.
Science Translational Medicine
|
November 6, 2015
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Daniel R Carter, Jayne Murray, Belamy B Cheung, et al.
Cell Reports
|
January 10, 2019
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
Yuting Sun, Madhavi Bandi, Timothy Lofton, et al.
Cancer Research
|
September 15, 2020
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib
Yuting Sun, Brooke A Meyers, Barbara Czako, et al.
Nature Medicine
|
June 13, 2018
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Jennifer R Molina, Yuting Sun, Marina Protopopova, et al.
Page
of 30